People

 AZTherapies has named Ernest D. Penachio to the newly created position of VP of Manufacturing Operations and CMC to oversee clinical and pre-commercial manufacturing, scale-up, and CMC content development for the company’s ALZT-OP1 inhaled cromolyn/oral… Read more . . .

Inhaled drug developer Pulmatrix has announced the appointment of Nocion Therapeutics CEO Rick Batycky to its board of directors. Batycky was a founder of Civitas Therapeutics, which developed Inbrija inhaled levodopa and which was acquired by Acorda… Read more . . .

Liquidia Technologies has announced the appointment of AbbVie VP of Global Commercial Development Katie Rielly-Gauvin to its board of directors for a term that will extend until company’s 2020 annual meeting. Prior to her position at… Read more . . .

Inhaled nitric oxide developer Third Pole Therapeutics has announced the appointment of Bill Athenson as its new Chief Executive Officer, succeeding founding CEO David Zapol. Athenson most recently served as CEO of Three Lakes Partners;… Read more . . .

Inhaled drug developer Vectura has announced the appointment of former Catalent executive Will Downie as CEO and Executive Director. Downie was most recently Senior VP, Global Sales and Marketing at Catalent and previously served in… Read more . . .

Contract manufacturer Experic, which offers a variety of services related to dry powder inhalers, has named Sherry Ann D’Iorio as Executive Director of Business Development. D’Iorio was most recently Senior Account Director of Business Development at… Read more . . .

Texas-based Pulmotect, which is developing an inhaled immune stimulant for the treatment of respiratory diseases, has announced the appointment of Colin Broom as CEO. Broom was most recently CEO of Nabriva Therapeutics and previously served… Read more . . .

Inhalation Sciences AB (ISAB) has announced that former ExScale Bio CEO Manoush Masarrat, who has been a member of the ISAB board of directors since January 2019, will succeed Lena Heffler as ISAB CEO. In… Read more . . .

Milestone Pharmaceuticals has announced the appointment of former Sanofi executive Amit Hasija as Chief Financial Officer and Executive VP of Corporate Development. Milestone’s etripamil, an intranasal calcium channel antagonist, is in Phase 3 development for the treatment… Read more . . .